454 Life Sciences Installs First Genome Sequencing System at the Broad Institute

-- Technology allows leading researchers to read genomes

up to 100 times faster --

Mar 25, 2005, 00:00 ET from 454 Life Sciences

    BRANFORD, Conn., March 25 /PRNewswire-FirstCall/ -- 454 Life Sciences, a
 majority-owned subsidiary of CuraGen Corporation (Nasdaq:   CRGN), announced
 today that it has sold and installed its first 454 Genome Sequencing System at
 the Genome Sequencing and Analysis program of the Broad Institute of MIT and
 Harvard, a research collaboration of the Massachusetts Institute of
 Technology, Harvard University and its hospitals and the Whitehead Institute
 for Biomedical Research.  The system, which utilizes novel technology
 developed by 454 Life Sciences, has the potential to perform sequencing 100
 times faster than conventional sequencing machines.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20050325/NEF002 )
     "Genome sequencing technology is entering a new era of development," said
 Eric Lander, Ph.D., director of the Broad Institute.  "The 454 Genome
 Sequencing System is the first of this next generation and we expect it to
 enable our researchers to tackle a wide range of applications."
     "We are honored to have the first 454 Genome Sequencing System installed
 at the Broad Institute.  The power of our system lies in its use of
 nanotechnology and microfluidics to allow massively parallel genomic
 sequencing, creating the potential for a single instrument to replace dozens
 of conventional sequencing machines," stated Christopher K. McLeod, interim
 President and CEO of 454 Life Sciences.  "We look forward to a productive
 relationship with the Broad as this new era of genomic sequencing begins, and
 anticipate that it will shape the future of this technology and applications
 for its use in genomics research."
     Chad Nusbaum, Ph.D., co-director of the Broad Institute Genome Sequencing
 and Analysis program, added "Our production team is enthusiastic about using
 the 454 system and we're excited about the potential of this technology to
 embark upon a variety of projects at the Broad."
     The Broad Institute is the first institution in the world to receive the
 454 Genome Sequencing System and will be utilizing proprietary system reagents
 sold by 454 Life Sciences for several ongoing projects.  The Broad Institute
 is a member of 454's Early Access Program, which enables select clients to
 work with 454's technology and instrumentation at 454's Measurement Service
 Center, as well as giving them the ability to obtain the first commercially
 available systems.
     454 Life Sciences provides whole genome sequencing solutions including
 instruments and reagents, as well as sequencing services to a broad range of
 customers.  Since early 2004, 454 Life Sciences' Measurement Service Center,
 located in Branford, CT, has routinely sequenced whole genomes for clients
 worldwide using 454's proprietary technology and instruments.  In addition to
 service-based genomic analysis, the Measurement Service Center provides
 training for researchers and staff using the 454 Genome Sequencing System.
     454's technology represents the first new approach for genomic sequencing
 to be commercialized in more than 20 years.  454's system enables one
 individual to prepare and sequence an entire genome after performing a single
 sample preparation, irrespective of the size of the genome being studied.  The
 hallmark of 454's technology is the radically different approach to sequencing
 which allows a single instrument to produce over 20 megabases (20,000,000
 bases) of sequencing per four hour run, totaling more that 100 times the
 capacity of instruments using the current standard technology.  454's
 technology is based on proprietary picoliter-technologies, patented light
 emitting sequencing chemistries, and state of the art informatics.  The
 patented Genome Sequencing System utilizes this technology and is a scalable,
 ultra-fast and cost-effective system for whole genome sequencing.
     About 454 Life Sciences
     454 Life Sciences is commercializing novel instrumentation and services
 for rapidly and comprehensively determining the nucleotide sequence -- "whole
 genome sequencing" -- of genomes.  The Company's instrument systems, based on
 proprietary picoliter-technologies, patented light emitting sequencing
 chemistry, and state of the art informatics, have 100 times the throughput of
 existing sequencing machines.  454 is marketing its services and instruments
 to pharmaceutical, biotechnology, biodefense, and agriculture companies as
 well as to universities and government agencies.  454 Life Sciences is a
 majority owned subsidiary of CuraGen Corporation.  Additional information is
 available at http://www.454.com.
     Safe Harbor
     This press release may contain forward-looking statements, including
 statements about (i) the ability of the 454 Genome Sequencing System to
 perform sequencing 100 times faster than conventional sequencing machines;
 (ii) the ability of the 454 Genome Sequencing System to enable the Broad
 Institute's researchers to tackle a wide range of applications; (iii) the
 ability of 454's single instrument to replace dozens of conventional
 sequencing machines; (iv) 454's future relationship with the Broad Institute;
 (v) the potential for 454's relationship with the Broad Institute to shape the
 future of genomic sequencing technology and applications for its use in
 genomics research; (vi) the potential for genomic sequencing technology to
 embark upon a variety of projects at the Broad Institute; and (vii) the Board
 Institute's plans to utilize proprietary system reagents sold by 454 for
 several ongoing projects.  Such statements are based on management's current
 expectations and are subject to a number of risks and uncertainties that could
 cause actual results to differ materially from those described in the forward-
 looking statements.  454 and CuraGen caution investors that there can be no
 assurance that actual results or business conditions will not differ
 materially from those projected or suggested in such forward-looking
 statements as a result of various factors, including, but not limited to, the
 following: the early stage of development of 454's products and technologies,
 CuraGen's stage of development as a genomics-based pharmaceutical company,
 uncertainties of clinical trials, government regulation and healthcare reform,
 technological uncertainty and product development risks, product liability
 exposure, uncertainty of additional funding, 454's and CuraGen's history of
 incurring losses and the uncertainty of achieving profitability, CuraGen's
 reliance on research collaborations and strategic alliances, competition,
 patent infringement claims against 454's and CuraGen's products, processes and
 technologies, the ability to protect 454's and CuraGen's patents and
 proprietary rights and uncertainties relating to commercialization rights.
 Please refer to CuraGen's Annual Report on Form 10-K for the period ended
 December 31, 2004 for a complete description of these risks.  454 and CuraGen
 disclaim any intention or obligation to update or revise any forward-looking
 statements, whether as a result of new information, future events, or
 otherwise, unless required by law.
     454 Life Sciences Contact:
      Christopher K. McLeod
      (877) 890-GNOM

SOURCE 454 Life Sciences